Hisamitsu Pharmaceutical Co., Inc.
Chiyoda-ku, Marunouchi 1-11-1
14 articles with Hisamitsu Pharmaceutical Co., Inc.
Hisamitsu America, Marketers of the Salonpas Line of Pain-Relieving Products, Announce Launch of Salonpas(R) Arthritis Pain Relief Gel
Hisamitsu America, a division of Hisamitsu Pharmaceutical Co., Inc., and the manufacturers of the Salonpas® line of pain-relieving products, announce the availability of the Salonpas® Arthritis Pain Relief Gel, which features the most prescribed topical pain medicine clinically proven to relieve arthritis pain in major joints.
U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
A transdermal patch may help to mitigate some of the challenges patients face with the management of their schizophrenia.
Key addition as Noven prepares for commercialization of HP-3070
Phase III Study Results for HP-3070 (Asenapine) Transdermal Patch for the Treatment of Schizophrenia to be Presented at the Society of Biological Psychiatry 74th Annual Meeting
New Drug Application for investigational product HP-3070 under FDA review
Hisamitsu Pharmaceutical Release: Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.
Hisamitsu Pharmaceutical announces that the transdermal patch for the treatment of schizophrenia (Development code: HP-3070, generic name: asenapine maleate, hereinafter referred to as “the investigational product”) achieved the primary endpoint of the Phase III clinical trial in the U.S.
Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals Inc.
Hisamitsu Pharmaceutical Announces Expiration of Initial Tender Offer Period for Outstanding Shares of Noven Pharmaceuticals Inc. and Commencement of Subsequent Offering Period
Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals Inc.
Hisamitsu Pharmaceutical Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals Inc.
Japan's Hisamitsu Pharmaceutical to Buy Noven Pharmaceuticals Inc. for $430 Million, To Expand U.S. Presence